Skip to main content

Table 1 Baseline demographic characteristics of patients

From: Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program

Mean ± SD

GHD (n = 115)

ISS (n = 27)

Chronological age, y

12.10 ± 3.00

10.76 ± 3.07

Male, n (%)

115 (100)

27 (100)

HSDS

−1.97 ± 0.78

−2.15 ± 0.72

Target HSDS

n = 96

− 0.36 ± 0.79

n = 24

− 0.80 ± 0.93

IGF-1 SDS

n = 66

− 1.15 ± 2.08

n = 17

− 0.65 ± 1.51

Bone age, y

n = 60

11.47 ± 2.76

n = 15

8.88 ± 3.11

BA/CA ratio

n = 60

0.91 ± 0.11

n = 15

0.85 ± 0.16

Peak GH, ng/mL

n = 50

6.25 ± 2.53

n = 5

20.04 ± 15.37

BMI, kg/m2

18.28 ± 3.17

17.83 ± 2.49

BMI SDS

−0.13 ± 1.13

0.09 ± 1.09

Tanner stage, n (%)

Not reported

31 (27)

2 (7)

  I

37 (32)

17 (63)

  II

27 (23)

5 (19)

  III

15 (13)

1 (4)

  IV

4 (3)

1 (4)

  V

1 (1)

1 (4)

  Total

115 (100)

27 (100)

  1. BA Bone age, BMI Body mass index, CA Chronologic age, GH Growth hormone, GHD Growth hormone deficiency, HSDS Height standard deviation score, IGF-1 Insulin-like growth factor 1, ISS Idiopathic short stature, SDS Standard deviation score